Transcriptional abnormalities in Huntington disease

Trends in Genetics

Volumn 19, Issue 5, 2003, Pages 233-238

  Sugars, Katharine L ^a   Rubinsztein, David C ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAGA PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENKEPHALIN; GROWTH FACTOR; HUNTINGTIN; MUTANT PROTEIN; NEUROPEPTIDE; NEUROTRANSMITTER RECEPTOR; NUCLEAR PROTEIN; POLYGLUTAMINE; PROTEIN; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; AUTOSOMAL DOMINANT DISORDER; BRAIN CORTEX; CELL NUCLEUS; CEREBELLUM; CORPUS STRIATUM; CYTOPLASM; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DISEASE MODEL; DISEASE SEVERITY; DNA MICROARRAY; DOWN REGULATION; EXON; GENE EXPRESSION; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC TRANSCRIPTION; GLUCOSE METABOLISM; HUMAN; HUNTINGTON CHOREA; IMMUNOPRECIPITATION; KENNEDY DISEASE; LIPID METABOLISM; NERVE DEGENERATION; NONHUMAN; NUCLEOTIDE REPEAT; OLIGOMERIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MOTIF; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SPINOCEREBELLAR DEGENERATION; SPONTANEOUS MUTATION; TRANSGENE; TRANSGENIC MOUSE; UPREGULATION;

MUS MUSCULUS;

EID: 0037408279     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-9525(03)00074-X     Document Type: Review

References (40)

1. Ho L., et al. The molecular biology of huntington's disease. Psychol. Med. 31:2001;3-14.
2. Sanchez I., et al. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature. 421:2003;373-379.
3. Martindale D., et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat. Genet. 18:1998;150-154.
4. DiFiglia M., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1997;1990-1993.
5. Dyer R.B., McMurray C.T. Mutant protein in Huntington disease is resistant to proteolysis in affected brain. Nat. Genet. 29:2001;270-278.
6. Kegel K.B., et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem. 277:2002;7466-7476.
7. Stott K., et al. Incorporation of glutamine repeats makes protein oligomerize: implications for neurodegenerative disorders. Proc. Natl. Acad. Sci. U. S. A. 92:1995;6509-6513.
8. Preisinger E., et al. Evidence for a recruitment and sequestration mechanism in Huntington's disease. Harper P.S., Perutz M., et al. Glutamine Repeats and Neurodegenerative Diseases: Molecular Aspects. 2001;127-139 Oxford University Press.
9. Wyttenbach A., et al. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum. Mol. Genet. 10:2001;1829-1845.
10. Kita H., et al. Modulation of polyglutamine-induced cell death by genes identified by expression profiling. Hum. Mol. Genet. 11:2002;2279-2287.
11. Luthi-Carter R., et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease parallel changes in muscle and brain. Hum. Mol. Genet. 11:2002;1911-1926.
12. Luthi-Carter R., et al. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet. 11:2002;1927-1937.
13. Chan E.Y.W., et al. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum. Mol. Genet. 11:2002;1939-1951.
14. Sipione S., et al. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analysis. Hum. Mol. Genet. 11:2002;1953-1965.
15. Zoghbi H.Y., Botas J. Mouse and fly models of neurodegeneration. Trends Genet. 18:2002;463-471.
16. Fain J.N., et al. Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation. Hum. Mol. Genet. 10:2001;145-152.
17. Lonze B.E., Ginty D.D. Function and Regulation of CREB family transcription factors in the nervous system. Neuron. 35:2002;605-623.
18. Nucifora F.C. Jr, et al. Interference by Huntingtin and Atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science. 291:2001;2423-2428.
19. McCampbell A., et al. CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. Genet. 9:2000;2197-2202.
20. II130, interfering with CREB-dependent transcription. Nat. Genet. 26:2000;29-36.
21. Mantamadiotis T., et al. Disruption of CREB function in brain leads to neurodegeneration. Nat. Genet. 31:2002;47-54.
22. Chai Y., et al. The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease. J. Biol. Chem. 276:2001;44889-44897.
23. Steffan J.S., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 413:2001;739-743.
24. Yu Z.-X., et al. Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum. Mol. Genet. 11:2002;905-914.
25. Stenoien D.L., et al. Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components. Nat. Cell Biol. 4:2002;806-810.
26. Chai Y., et al. Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 99:2002;9310-9315.
27. Dunah A.W., et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science. 296:2002;2238-2243.
28. Li S.-H., et al. Interaction of Huntington disease protein with transciptional activator Sp1. Mol. Cell. Biol. 22:2002;1277-1287.
29. U M., et al. Extended polyglutamine selectively interacts with caspase-8 and -10 in nuclear aggregates. Cell Death Differ. 8:2001;377-386.
30. Mitsui K., et al. Purification of polyglutamine aggregates and identification of elongation factor-1a and heat shock protein 84 as aggregate-interacting proteins. J. Neurosci. 22:2002;9267-9277.
31. Neil F., et al. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:2001;1552-1555.
32. Hockly E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 100:2003;2041-2046.
33. Freiman R.N., Tjian R. A glutamine-rich trail leads to transcription factors. Science. 296:2002;2149-2150.
34. Steffan J.S., et al. The huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6763-6768.
35. Li F., et al. Ataxin-3 is a histone binding protein with two independent transcriptional corepressor activities. J. Biol. Chem. 277:2002;45004-45012.
36. Boutell J.M., et al. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum. Mol. Genet. 8:1999;1647-1655.
37. Takano H., Gusella J.F. The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-κB/Rel/dorsal family transcription factor. BMC Neurosci. 3:2002;15-27.
38. Holbert S., et al. The Gln-Ala repeat transcriptional activitor CA150 interacts with huntingtin: neuropathologic and genetic eveidence for a role in Huntington's disease pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 98:2001;1811-1816.
39. Kim S., et al. Polyglutamine protein aggregates are dynamic. Nat. Cell Biol. 4:2002;826-831.
40. Carmichael J., et al. Glycogen synthase kinase-3b inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J. Biol. Chem. 277:2002;33791-33798.